Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante, Leslie Anne Fecher, Gerald Steven Falchook et al. · The Lancet Oncology · 2012
Cited by 552 works. doi:10.1016/s1470-2045(12)70270-x
Authors
- Jeffrey R. Infante
- Leslie Anne Fecher
- Gerald Steven Falchook
- Sujatha Nallapareddy
- Michael S. Gordon
- Carlos Roberto Becerra
- Douglas James DeMarini
- Donna S. Cox
- Yanmei Xu
- Shannon R. Morris
- Vijay G. R. Peddareddigari
- Ngocdiep T. Le
- Lowell L. Hart
- Johanna C. Bendell
- Gail Eckhardt
- Razelle Kurzrock
- Keith T. Flaherty
- Howard A. Burris
- Wells A. Messersmith
References
- A synthetic inhibitor of the mitogen-activated protein kinase cascade.
- BRAF mutation predicts sensitivity to MEK inhibition
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
- Accelerated Titration Designs for Phase I Clinical Trials in Oncology
- Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
- p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial